Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
RXPC meger expected with Direct Labs!!!!!!!! .03
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by Egg Inspector: [QB] PR 09:29 sure I am late :) Rx Processing Corp. Analysis of Developing Shareholder Corporate Capitol Market Business Wire - July 11, 2006 09:29 WILMINGTON, Del., Jul 11, 2006 (BUSINESS WIRE) -- Rx Processing Corporation (OTC: RXPC) recently modified its approach towards listing our shareholder on a NASDAQ exchange. Furthering shareholders knowledge and understanding of our true competition and future shareholder market capital for the subsidiary and why $48 was agreed upon for the offering price. Rx Processing Corp.'s shareholders major competition in sourcing prescription medications are Canada Drugs, a Canadian corporation with over 175,000 patients and Rx-payments Ltd. of Israel with assumed revenues in excess of $1 billion US. These groups work internationally and have greater flexibility servicing clients with prescription medications than U.S. corporations in a direct to consumer business model. Rx Processing Corp. shareholders will have many advantages over the competition; we can transact and conduct business in a HIPPA compliant regulatory environment to further ensure customer identity information is safe and residing in the United States while receiving a full compliment of prescription medication. We learned from innovators in prescription medication sourcing and direct laboratory testing and have listened to how to properly conduct operations as a reporting corporation. This understanding leads to our innovative approaches to methods utilized by international groups that achieved substantial success in attaining U.S. customers. We, however, possess a business model and track record of seeding this developing market with open public communications and a true focus on benevolently affecting U.S. Citizens health care. Our shareholder future market capitalization is as follows for the prescription medication sourcing business for the under and uninsured. One client conservatively represents $2500 annually in prescription medication sales with a built in 15%-40% net profit margin on brand and lower cost generic medications respectively. This $375-$650+ a year in potential net profits per client with a corporate capital market multiple of 7 years equals a market value of $2650-$4550 per client. Figure each future corporate or affiliate location gains 1 client per day and they order a 90-day supply of Lipitor for $228 and tell their neighbors over coffee within a 90-day time frame, we effectively have a potential growth curve of 50-100% every ninety days for a number of years. Conservatively, the potential number of clients we attain in the next 7 years could reach 100,000+. Adding in the intent to still acquire Direct Laboratory Services Inc. (1) for our shareholders in the corporation now forming and the potential for additional strategic acquisitions, a valuation of $48 per share is wholly justified. Peter Fiorillo commented, "This market capitalization is significant, sizable to service our market, and we are aggressively positioning to keep that market capital in the United States to support Americans." About Rx Processing Corp. - http://www.rxprocessingcorp.com Rx Processing Corp. is positioning shareholders to become significant owners in a listed NASDAQ corporation to provide prescription medications and preventative health laboratory testing to U.S. citizens, corporations, and members, through CLIA-certified patient service centers, for their lab testing and licensed pharmacies in the United States and around the world. The company provides access to approved brand-name and generic medications, and hundreds of lab tests with access to 4,000+ CLIA-certified patient service centers for their lab testing. Rx Processing Corp. estimates that more than 44 million United States citizens would benefit from the company's affordable prescription medication and laboratory testing programs. Safe Harbor Statement All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including those about the company's future expectations, revenues and earnings, and all other forward-looking statements (i.e., operational results and sales) are subject to assumptions and beliefs based on current information known to the company and factors that are subject to uncertainties, risk and other influences, which are outside the company's control, and may yield results differing materially from those anticipated. (1) The option agreement to acquire Direct Laboratory Services Expired without execution June 15th 2006. SOURCE: Rx Processing Corporation Rx Processing Corporation, Wilmington Tim Gillesse, 800-576-7055 Copyright Business Wire 2006 [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2